Craig Hopkinson, M.D.

Craig Hopkinson, M.D., serves as Alkermes’ Executive Vice President of Research & Development and Chief Medical Officer. In this role, Dr. Hopkinson leads the company’s Discovery, Pharmaceutical Development, Early Stage Clinical Development, Late Stage Clinical Development, Regulatory Affairs, Clinical Operations, Project Management Office and Medical Affairs functions. He is responsible for the strategic development and execution of clinical development programs for the company’s pipeline of drug candidates.

Dr. Hopkinson has nearly 30 years of experience building and leading clinical development organizations and medical affairs groups. He has led multidisciplinary development teams in a range of therapeutic areas, including neuroscience, oncology, gastroenterology, infectious diseases, cardiovascular conditions, inflammation, genetic diseases, hematology and neurodegenerative diseases. Before joining Alkermes in 2017, Dr. Hopkinson served as Senior Vice President of Medicines Development and Head of Global Medical Affairs at Vertex Pharmaceuticals. Prior to this role, Dr. Hopkinson held various leadership positions at Eisai Pharmaceuticals, Elan Pharmaceuticals, Actelion Pharmaceuticals and Pfizer. He previously served on the Board of Directors of Albireo Pharma, before its acquisition by Ipsen.

Dr. Hopkinson earned a Bachelor of Medicine and Bachelor of Surgery at the University of the Orange Free State in South Africa.